Table 4.
AMR patterns of N. gonorrhoeae isolated from the study participants in northwestern Ethiopia; March to August 2022
| Antimicrobial Agent | Antimicrobial resistance pattern of Neisseria gonorrheae (n = 21) | |||||
|---|---|---|---|---|---|---|
| Disc Diffusion result | E-test (MIC) result | |||||
| S n(%) | I n (%) | R n(%) | S n (%) | I n (%) | R n (%) | |
| Ceftriaxone | 14 (66.7) | – | 7(33.3) | 21 (100) | 0 | 0 |
| Cefixime | 12 (57.1) | – | 9 (42.9) | 21 (100) | 0 | 0 |
| Azithromycin | 12 (57.1) | – | 9 (42.9) | 21 (100) | 0 | 0 |
| Ciprofloxacin | 6(28.6) | 4(19) | 11(52.4) | 3(14.3) | – | 18(85.7) |
| Spectinomycine | 13 (61.9) | 3 (14.3) | 5 (23.8) | 21 (100) | 0 | 0 |
| Tetracycline | 0 | – | 21(100) | 0 | 0 | 21 (100) |
| Penicillin | 0 | 3 (14.3) | 18 (85.7) | 3(14.3) | 0 | 18(85.7) |
| Cefoxitine | 13 (61.9) | 2 (9.5) | 6 (28.6) | – | – | – |
| Gentamycin | 5 (23.8) | 10 (47.6) | 6 (28.6) | – | – | – |
| Amikacine | 13 (61.9) | 3 (14.3) | 5 (23.8) | – | – | – |
| Clindamycin | 12 (57.1) | 5 (23.8) | 4 (19) | – | – | – |
Key: AMR antimicrobial resistance, MIC minimum inhibitory concentration test, S susceptible, I intermediate, R resistance, n number